Viadur

Viadur was a brand name used for a subcutaneous implant that delivered leuprolide acetate, a gonadotropin-releasing hormone (GnRH) agonist, for continuous suppression of the hypothalamic-pituitary-gonadal axis in men with advanced prostate cancer. The device was implanted by a clinician under the skin and was designed to release leuprolide acetate steadily for up to 12 months, providing a form of chemical castration by lowering testosterone to castration levels.

Administration and mechanism: A single insertion provided sustained suppression of luteinizing hormone and follicle-stimulating hormone, reducing testosterone production from the testes. This suppression helps slow the growth of testosterone-dependent tumors.

Indications: Primarily used for the palliation of advanced or metastatic prostate cancer in patients whose disease is advanced or progressive and who require suppression of testosterone. It was intended as an alternative to periodic injections of GnRH agonists.

Side effects: Treatment with GnRH agonists, including leuprolide, can cause hot flashes, night sweats, reduced libido, erectile dysfunction, fatigue, and bone mineral density loss. Other potential adverse effects include injection-site reactions, edema, mood changes, and rare cardiovascular complications.

Status: Viadur has been largely supplanted by newer long-acting leuprolide formulations and similar implants in various markets. Availability varies by country, and the brand may be discontinued in some regions. As with all hormone therapies, treatment decisions should be guided by a clinician.